Risk of nephrolithiasis with finerenone versus other chronic kidney disease medications: a comparative real-world evidence study

Keyword: Retrospective Cohort Study

Publisher: Nature.com

Published: Aug 18, 2026

Finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has shown renoprotective benefits for chronic kidney disease (CKD) in people with type 2 diabetes (T2DM); however, its impact … [+1525 chars]

Read Full Story ↗